Zopiclone - Is it a phormacologic agent for abuse?

被引:0
|
作者
Cimolai, Nevio [1 ]
机构
[1] Childrens & Womens Hlth Ctr British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6H 3V4, Canada
关键词
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
OBJECTIVE To determine whether the hypnosedative drug zopiclone could be an agent for abuse. SOURCES OF INFORMATION Using MEDLINE and PubMed, English-language medical literature was systematically reviewed for reports of direct drug abuse and addiction. A review was also conducted for clinical trials or patient series that discussed issues of addiction or rebound effects. MAIN MESSAGE Evidence of drug abuse and dependency was found in case reports and small patient series. Dependency symptoms of severe rebound, severe anxiety, tremor, palpitations, tachycardia, and seizures were observed in some patients after withdrawal. Abuse occurred more commonly among patients with previous drug abuse or psychiatric illnesses. Many clinical trials have found evidence of rebound insomnia after recommended dosages were stopped, albeit for a minority of patients. Comparative studies of zopiclone and benzodiazepines or other "Z" drugs are conflicting. CONCLUSION Zopiclone has the potential for being an agent of abuse and addiction. While many have suggested that the addictive potential for this and other "Z" drugs is less than for most benzodiazepines, caution should be taken when prescribing this agent for insomnia. ideally, prescriptions should be given for a short period of time and within the recommended dosage guidelines.
引用
收藏
页码:2124 / 2129
页数:6
相关论文
共 50 条
  • [31] PHARMACOLOGICAL STUDIES ON ZOPICLONE
    JULOU, L
    BARDONE, MC
    BLANCHARD, JC
    GARRET, C
    STUTZMANN, JM
    [J]. PHARMACOLOGY, 1983, 27 : 46 - 58
  • [32] Electrochemical oxidation of zopiclone
    Taborsky, Jakub
    Svidrnoch, Martin
    Kurka, Ondrej
    Borovcova, Lucie
    Bednar, Petr
    Bartak, Petr
    Skopalova, Jana
    [J]. MONATSHEFTE FUR CHEMIE, 2016, 147 (01): : 53 - 60
  • [33] BEHAVIORAL PHARMACOLOGY OF ZOPICLONE
    UEKI, S
    [J]. SLEEP, 1987, 10 : 1 - 6
  • [34] PHARMACOKINETICS AND METABOLISM OF ZOPICLONE
    GAILLOT, J
    HEUSSE, D
    HOUGTON, GW
    AURELE, JM
    DREYFUS, JF
    [J]. PHARMACOLOGY, 1983, 27 : 76 - 91
  • [35] Parenteral Formulation of Zopiclone
    Swamy, P. V.
    Sushma, P.
    Chirag, G.
    Prasad, K.
    Ali, M. Younus
    Raju, S. A.
    [J]. INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2008, 70 (01) : 99 - U22
  • [36] Zopiclone poisoning - Reply
    VanBocxlaer, J
    Meyer, E
    Clauwaert, K
    Lambert, W
    Piette, M
    DeLeenheer, A
    [J]. JOURNAL OF ANALYTICAL TOXICOLOGY, 1996, 20 (04) : 274 - 274
  • [37] The mechanism of action of zopiclone
    Doble, A
    Canton, T
    Malgouris, C
    Stutzmann, JM
    Piot, O
    Bardone, MC
    Pauchet, C
    Blanchard, JC
    [J]. EUROPEAN PSYCHIATRY, 1995, 10 : S117 - S128
  • [38] Residual sequelae of zopiclone
    Nicholson, AN
    [J]. REVIEWS IN CONTEMPORARY PHARMACOTHERAPY, 1998, 9 (02): : 123 - 129
  • [39] Zopiclone concentrations in oral fluid and blood after, administration of therapeutic doses of zopiclone
    Hjelmeland, Knut
    Gustavsen, Ingebjorg
    Oiestad, Elisabeth Leere
    Oiestad, Ase Marit Leere
    Hoiseth, Gudrun
    Morland, Jorg
    [J]. FORENSIC SCIENCE INTERNATIONAL, 2017, 278 : 177 - 183
  • [40] Topical steroid abuse: Its use as a depigmenting agent
    Nnoruka, Edith
    Okoye, Obiefuna
    [J]. JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 2006, 98 (06) : 934 - 939